BLRX vs. EGRX, HCWB, EQ, LTRN, CLNN, RPHM, IMMX, CKPT, CELU, and ELDN
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Eagle Pharmaceuticals (EGRX), HCW Biologics (HCWB), Equillium (EQ), Lantern Pharma (LTRN), Clene (CLNN), Reneo Pharmaceuticals (RPHM), Immix Biopharma (IMMX), Checkpoint Therapeutics (CKPT), Celularity (CELU), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical preparations" industry.
Eagle Pharmaceuticals (NASDAQ:EGRX) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.
85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Eagle Pharmaceuticals has higher revenue and earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
BioLineRx received 91 more outperform votes than Eagle Pharmaceuticals when rated by MarketBeat users. Likewise, 73.32% of users gave BioLineRx an outperform vote while only 70.79% of users gave Eagle Pharmaceuticals an outperform vote.
Eagle Pharmaceuticals presently has a consensus target price of $17.00, indicating a potential upside of 285.49%. BioLineRx has a consensus target price of $21.00, indicating a potential upside of 2,988.24%. Given Eagle Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioLineRx is more favorable than Eagle Pharmaceuticals.
In the previous week, Eagle Pharmaceuticals had 2 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Eagle Pharmaceuticals and 0 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.99 beat Eagle Pharmaceuticals' score of 0.00 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.
BioLineRx's return on equity of 0.00% beat Eagle Pharmaceuticals' return on equity.
Eagle Pharmaceuticals has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.
Summary
Eagle Pharmaceuticals beats BioLineRx on 10 of the 17 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
